Impact of stents and abciximab on survival from cardiogenic shock treated with percutaneous coronary intervention

Catheterization and Cardiovascular Interventions

Volumn 65, Issue 1, 2005, Pages 25-33

  Huang, Raymond ^a   Sacks, Jerome ^b   Thai, Hoang ^a   Goldman, Steven ^a   Morrison, Douglass A ^a,d   Barbiere, Charles ^c   Ohm, Janet ^a  

^a UNIVERSITY OF ARIZONA   (United States)

^b Hines Veteran's Affairs Hospital   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d Cardiac Catheterization Laboratories   (United States)

Author keywords

Cardiogenic shock; Coronary artery disease; Myocardial infarction; Percutaneous coronary intervention; Reperfusion; Stents

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOGENIC SHOCK; COMORBIDITY; CONTROLLED STUDY; CORONARY STENT; FEMALE; HEART CATHETERIZATION; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; ST SEGMENT ELEVATION; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; BLOOD VESSEL PROSTHESIS IMPLANTATION; COATED MATERIALS, BIOCOMPATIBLE; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OBSERVATION; PLATELET AGGREGATION INHIBITORS; RETROSPECTIVE STUDIES; SHOCK, CARDIOGENIC; STENTS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 18044391074     PISSN: 15221946     EISSN: None     Source Type: Journal    
DOI: 10.1002/ccd.20334     Document Type: Article

References (59)

1. ACC/AHA Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1996;28:1332-1428.
2. ACC/AHA Task Force on Practice Guidelines. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. J Am Coll Cardiol 1999;34:890-911.
3. ACC/AHA Task Force on Practice Guidelines. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2000;36:971-1062.
4. Ashby DT, Stone GW, Moses JW. Cardiogenic shock in acute myocardial infarction. Catheter Cardiovas Interv 2003;59:34-43.
5. Goldberg RJ, Gore JM, Alpert J, et al. Cardiogenic shock with acute myocardial infarction: incidence and mortality from a community wide perspective, 1975-1988. N Engl J Med 1991;325:1117-1122.
6. Goldberg RJ, Samd NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med 1999;340:1162-1168.
7. Gruppo Italiano per Studio della Streptochinasi nell'Infarto Miocardio (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-401.
8. Gruppo Italiano per Studio della Streptochinasi nell'Infarto Miocardio (GISSI). Long term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Lancet 1987;11:871-874.
9. Bates ER, Topol EJ. Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. J Am Coll Cardiol 1991;18:1077-1084.
10. O'Keefe IH, Bailey WL, Rutherford BD, Hartzler GO. Primary angioplasty for acute myocardial infarction in 1, 000 consecutive patients: results in an unselected population and high-risk subgroups. Am J Cardiol 1993;72:107G-115G.
11. Hartzler GO, Rutherford BD, McConahay DR, Johnson WL, McCallister BD, Gura GM, Conn RC, Crockett JE. Percutaneous transluminal coronary angioplasty with and without thrombolytic therapy for treatment of acute myocardial infarction. Am Heart J 1983;106:965-973.
12. Lee L, Bates ER, Pitt B, Walton JA, Laufer N, O'Neill WW. Percutaneous transluminal coronary angioplasty improves survival in acute myocardial infarction complicated by cardiogenic shock. Circulation 1988;78:1345-1351.
13. Klein LW. Optimal therapy for cardiogenic shock: the emerging role of coronary angioplasty. J Am Coll Cardiol 1992;19:654-656.
14. Hibbard MD, Holmes DR Jr, Bailey KR, Reeder OS, Bresnahan JF, Gersh BJ. Percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. J Am Coll Cardiol 1992;19:639-646.
15. Lee L, Erbel R, Brown TM, Laufer N, Meyer I, O'Neill WW. Multicenter registry of angioplasty therapy of cardiogenic shock: initial and long-term survival. J. Am Coll Cardiol 1991;17:599-603.
16. Gacioch GM, Ellis SG, Lee L, et al. Cardiogenic shock complicating acute myocardial infarction: the use of coronary angioplasty and the integration of the new support devices into patient management. J Am Coll Cardiol 1992;19:647-653.
17. Seydoux C, Goy JJ, Beuret P, et al. Effectiveness of percutaneous transluminal coronary angioplasty in cardiogenic shock during acute myocardial infarction. Am J Cardiol 1992;69:968-969.
18. O'Neill WW. Angioplasty therapy of cardiogenic shock: are randomized trials necessary? J Am Coll Cardiol 1992;19:915-917.
19. Bengtson JR, Kaplan AJ, Pieper KS, et al. Prognosis in cardiogenic shock after acute myocardial infarction in the interventional era. J Am Coll Cardiol 1992;20:1482-1489.
20. Moosvi AR, Khaja F, Villanueva L, Gheorghiade M, Douthat L, Goldstein S. Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction. J Am Coll Cardiol 1992;19:907-914.
21. Hochman JS, Sleeper LA, Webb IG, Sanbom TA, White HD, Talley JD II, Huller CE, Jacos AK, Slater IN, McKinlay SM, Lejemtel TH, for the SHOCK investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999;341:625-634.
22. Ryan TJ. Early revascularization in cardiogenic shock: a positive view of a negative trial. N Engl J Med 1999;341:687-688.
23. Urban P, Stauffer JC, Bleed D, Khatchatrian N, Amann W, Bertel O, van den Brand M, Danchin N, Kaufmann U, Meier B, Machecourt J, Pfisterer MA. Randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction: the (Swiss) multicenter trial of angioplasty for shock-(S)MASH. Eur Heart J 1999;20:1030-1038.
24. Lincoff AM, Popma II, Ellis SG, Vogel RA, Topol EJ. Percutaneous support devices for high risk or complicated coronary angioplasty. J Am Coll Cardiol 1991;17:770-780.
25. Kahn JK, Rutherford BD, McConahay DR, Johnson WL, Giorgi LV, Hartzler GO. Supported "high risk" coronary angioplasty using intraaortic balloon pump counterpulsation. J Am Coll Cardiol 1990;15:511-515.
26. Vogel RA, Shawl F, Tommaso C, et al. Initial report of the National Registry of Elective Cardiopulmonary Bypass Supported Coronary Angioplasty. J Am Coll Cardiol 1990;15:23-29.
27. Overlie PA. Emergency use of portable cardiopulmonary bypass. Cathet Cardiovasc Diagn 1990;20:27-31.
28. Pavlides GS, Hauser AM, Stack RK, et al. Effect of peripheral cardio-pulmonary bypass on left ventricular size, afterload and myocardial function during elective supported coronary angioplasty. J Am Coll Cardiol 1991;18:499-505.
29. Giri S, Mitchel J, Azar RR, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;89:126-131.
30. Antoniucci D, Valenti R, Migliorini A, et al. Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002;90:353-357.
31. Chan AW, Chew DP, Bhatt DL, et al. Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002;89:132-136.
32. Antoniucci D, Valenti R, Santoro GM, et al. Systematic direct angioplasty and stent-supported direct angioplasty therapy for cardiogenic shock complicating acute myocardial infarction: in-hospital and Long term survival. J Am Coll Cardiol 1998;31:294-300.
33. Fabbiocchi F, Bartorelli AL, Montorsi P, et al. Elective coronary stent implantation in cardiogenic shock complicating acute myocardial infarction: in-hospital and six-month clinical and angiographic results. Catheter Cardiovasc Interv 2000;50:384-389.
34. Hochman JS, Boland J, Sleeper LA, et al., for the SHOCK registry investigators. Current spectrum of cardiogenic shock and effect of early revascularization on mortality: results of an international registry. Circulation 1995;91:873-881.
35. Dauerman HL, Goldberg RI, White K, et al., Revascularization, stenting, and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;90:838-842.
36. Hochman JS, Buller CE, Sleeper LA, et al., for the SHOCK investigators. Cardiogenic shock complicating acute myocardial infarction: etiologies, management and outcome-a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1063-1070.
37. Menon V, White H, LeJemtel T, et al., for the SHOCK investigators. The clinical profile of patients with suspected cardiogenic shock due to predominant left ventricular failure: a report form the SHOCK trial registry. J Am Coll Cardiol 2000;36:1071-1076.
38. Wong SC, Sanborn TA, Sleeper LA, et al., for the SHOCK investigators. Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1077-1083.
39. Jacobs AK, French JK, Co J, et al., for the SHOCK trial investigators. Cardiogenic shock with non-ST-segment elevation myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1091-1096.
40. Thompson CR, Buller CE, Sleeper LA, et al., for the SHOCK investigators. Cardiogenic shock due to acute severe mitral regurgitation complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1104-1109.
41. Menon V, Webb JG, Hillis LD, et al., for the SHOCK investigators. Outcome and profile of ventricular septal rupture with cardiogenic shock after myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1110-1116.
42. Slater J, Brown RJ, Antonelli TA, et al., for the SHOCK trial investigators. Cardiogenic shock due to cardiac free-wall rupture or tamponade after acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1117-1122.
43. Sanborn TA, Sleeper LA, Bates ER, et al., for the SHOCK investigators. Impact of thrombolysis, intra-aortic balloon counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK trial registry. J Am Coll Cardiol 2000;36:1123-1129.
44. Antoniucci D, Santoro G, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol 1998;31:1234-1239.
45. Stone GW, Brodie BR, Griffin II, Morice MC, Constantini C, St Goar FG, Overlie PA, Popma II, McDonnell J, Jones D, O'Neill WW, Grines CL. Prospective, multicenter study of the safety and feasibility of primary stenting in acute myocardial infarction: in-hospital and 30-day results of the PAMI stent pilot trial. J Am Coll Cardiol 1998;31:23-30.
46. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, Brodie BR, Madonna O, Eijgelshoven M, Lansky AI, O'Neill WW, Morice MC, for the Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med 1999;341:1949-1956.
47. Schomig A, Neumann FJ, Walter H. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997;29:28-34.
48. Bertrand ME, Legrand V, Boland J. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the full anticoagulation versus aspirin and ticlopidine (FANTASTIC) study. Circulation 1998;98:1597-1603.
49. CAPTURE investigators. Randomized placebo-controlled trial of effect of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997;349:1429-1435.
50. EPISTENT investigators. Randomized placebo-controlled and balloon-angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998;352:87-92.
51. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, Weisman HP, Topot EJ, for the EPIC investigators. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996;77:1045-1051.
52. Brener SJ, Barr LA, Burchenal JEB, Katz S, George BS, Jones AA, Cohen ED, Gainey PC, White HJ, Cheek HB, Moses JW, Moliterno DJ, Effron MB, Topot EJ, on behalf of the ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) investigators. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998;98:734-741.
53. EPILOG investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336:1689-1696.
54. Morrison DA, Crowley ST, Bies R, Barbiere CC. Systolic blood pressure response to percutaneous transluminal coronary angioplasty for cardiogenic shock. Am J Cardiol 1995;76:313-314.
55. Hennekens CH, Buring JE, editors. Epidemiology in medicine. Boston: Little, Brown; 1987. p 272-326.
56. Elwood M. Critical appraisal of epidemiological studies and clinical trials, 2nd ed. Oxford: Oxford University Press; 1998. p 94-160.
57. Morrison DA, Sethi G, Sacks J, et al. A multicenter, randomized trial of percutaneous coronary intervention versus bypass surgery in high-risk unstable angina patients. Controlled Clin Trials 1999;20:601-619.
58. Morrison DA, Sethi G, Sacks, J, Henderson W, Grover F, Sedlis S, et al., for the AWESOME coinvestigators. Angina With Extremely Serious Operative Mortality Evaluation (AWESOME): percutaneous coronary intervention versus coronary artery bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass-a multicenter randomized trial. J Am Coll Cardiol 2001;38:143-149.
59. Morrison DA, Sethi G, Sacks, J, Henderson W, Grover F, Sedlis S, et al., for the AWESOME coinvestigators. Percutaneous coronary intervention versus coronary bypass graft surgery for patients with medically refractory myocardial ischemia and risk factors for adverse outcomes with bypass: the VA AWESOME multicenter registry-comparison with the randomized clinical trial. J Am Coll Cardiol 2002;39:266-273.